Cardinal Health's Infrastructure Narrative Masks Rising Execution and Policy Risks

What happened

A bullish Zacks article positions Cardinal Health as the emerging backbone of U.S. healthcare, highlighting its expansion into specialty care, logistics, and nuclear medicine. However, the latest DeepValue report assigns a POTENTIAL SELL rating, noting the stock trades at ~22x FY26 non-GAAP EPS with negative book equity and rising leverage from $5.3B of acquisitions. The company's FY25 GAAP EPS of $6.45 versus non-GAAP $8.24 reveals a growing gap driven by $464M of amortization and $126M of acquisition-related compensation, raising questions about earnings quality. Customer concentration remains a key risk with CVS accounting for ~30% of revenue, while IRA drug pricing negotiations threaten specialty margins that underpin the growth story. The article's “backbone” framing overlooks these fundamental concerns, suggesting the market may be discounting structural headwinds in its current valuation above $214.

Implication

The article's upbeat portrayal of Cardinal as a healthcare infrastructure leader conflicts with the DeepValue report's detailed warnings on valuation, earnings quality, and policy exposure. At $214, the stock prices in flawless execution of the specialty/MSO pivot, yet the GAAP-to-non-GAAP earnings gap continues to widen, leverage is elevated, and high customer concentration (CVS at ~30% of revenue) leaves little room for error. Near-term catalysts like FY26 EPS guidance of at least $10 appear achievable, but the risk lies in FY27 and beyond, where no explicit framework exists and IRA impacts intensify. Investors should avoid adding at current levels and instead use rallies above $210–$230 to reduce exposure, waiting for a pullback toward $185 or clearer evidence of sustainable GAAP earnings growth before re-engaging. The crowded momentum ownership amplifies the risk of a sharp de-rating if any guidance wobble occurs, making this a high-conviction hold-small or lighten scenario rather than a buy.

Thesis delta

The market narrative has shifted from skeptical repair story to euphoric momentum stock, with recent articles celebrating Cardinal’s guidance raises and specialty growth without acknowledging the structural challenges. The DeepValue analysis, however, indicates that earnings quality is deteriorating, leverage is rising, and the margin of safety is absent at current prices. The prudent stance is to fade the enthusiasm and focus on the growing gap between reported and adjusted earnings, as well as the intensifying regulatory threats that could compress margins faster than the market expects.